List of Excipients in API cabozantinib laurylsulfate
Excipients in NDA-approved (novel) drugs containing cabozantinib laurylsulfate
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Handa Pharma | OMCAZIO | cabozantinib laurylsulfate | 17201-011 | AMMONIA | 2044-01-30 |
| Handa Pharma | OMCAZIO | cabozantinib laurylsulfate | 17201-011 | ASCORBYL PALMITATE | 2044-01-30 |
| Handa Pharma | OMCAZIO | cabozantinib laurylsulfate | 17201-011 | FERROSOFERRIC OXIDE | 2044-01-30 |
| Handa Pharma | OMCAZIO | cabozantinib laurylsulfate | 17201-011 | GELATIN | 2044-01-30 |
| Handa Pharma | OMCAZIO | cabozantinib laurylsulfate | 17201-011 | POTASSIUM HYDROXIDE | 2044-01-30 |
| Handa Pharma | OMCAZIO | cabozantinib laurylsulfate | 17201-011 | PROPYLENE GLYCOL | 2044-01-30 |
| Handa Pharma | OMCAZIO | cabozantinib laurylsulfate | 17201-011 | SHELLAC | 2044-01-30 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for cabozantinib laurylsulfate
Excipient focus: AMMONIA
cabozantinib laurylsulfate drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ASCORBYL PALMITATE
cabozantinib laurylsulfate drug variants containing ASCORBYL PALMITATE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing ASCORBYL PALMITATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
cabozantinib laurylsulfate drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
cabozantinib laurylsulfate drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM HYDROXIDE
cabozantinib laurylsulfate drug variants containing POTASSIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing POTASSIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
cabozantinib laurylsulfate drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
cabozantinib laurylsulfate drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: STEAROYL POLYOXYL-32 GLYCERIDES
cabozantinib laurylsulfate drug variants containing STEAROYL POLYOXYL-32 GLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing STEAROYL POLYOXYL-32 GLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
cabozantinib laurylsulfate drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TOCOPHEROL
cabozantinib laurylsulfate drug variants containing TOCOPHEROL
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib laurylsulfate drug variants not containing TOCOPHEROL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch